TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol

IntroductionStereotactic body radiotherapy (SBRT) is a non-invasive alternative to surgery for the treatment of non-metastatic prostate cancer (PC). The objectives of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation (NINJA) clinical trial are to compare tw...

Full description

Bibliographic Details
Main Authors: Jeremy Millar, Jarad Martin, Paul Keall, Shankar Siva, Peter Greer, David Christie, Jason Dowling, David Pryor, Peter Chong, Nicholas McLeod, Avi Raman, James Lynam, Joanne Smart, Declan G Murphy, Keen Hun Tai, Lois Holloway, Amy Hayden, Tee Lim, Tanya Holt, Mark Sidhom
Format: Article
Language:English
Published: BMJ Publishing Group 2019-08-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/9/8/e030731.full
id doaj-e79f4f8788cf40b08288a3571ae571e3
record_format Article
spelling doaj-e79f4f8788cf40b08288a3571ae571e32021-03-22T09:01:59ZengBMJ Publishing GroupBMJ Open2044-60552019-08-019810.1136/bmjopen-2019-030731TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocolJeremy MillarJarad MartinPaul KeallShankar Siva0Peter GreerDavid ChristieJason DowlingDavid PryorPeter ChongNicholas McLeodAvi RamanJames LynamJoanne SmartDeclan G MurphyKeen Hun TaiLois HollowayAmy HaydenTee LimTanya HoltMark SidhomDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaIntroductionStereotactic body radiotherapy (SBRT) is a non-invasive alternative to surgery for the treatment of non-metastatic prostate cancer (PC). The objectives of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation (NINJA) clinical trial are to compare two emerging SBRT regimens for efficacy with technical substudies focussing on MRI only planning and the use of knowledge-based planning (KBP) to assess radiotherapy plan quality.Methods and analysisEligible patients must have biopsy-proven unfavourable intermediate or favourable high-risk PC, have an Eastern Collaborative Oncology Group (ECOG) performance status 0-1 and provide written informed consent. All patients will receive 6 months in total of androgen deprivation therapy. Patients will be randomised to one of two SBRT regimens. The first will be 40 Gy in five fractions given on alternating days (SBRT monotherapy). The second will be 20 Gy in two fractions given 1 week apart followed 2 weeks later by 36 Gy in 12 fractions given five times per week (virtual high-dose rate boost (HDRB)). The primary efficacy outcome will be biochemical clinical control at 5 years. Secondary endpoints for the initial portion of NINJA look at the transition of centres towards MRI only planning and the impact of KBP on real-time (RT) plan assessment. The first 150 men will demonstrate accrual feasibility as well as addressing the KBP and MRI planning aims, prior to proceeding with total accrual to 472 patients as a phase III randomised controlled trial.Ethics and disseminationNINJA is a multicentre cooperative clinical trial comparing two SBRT regimens for men with PC. It builds on promising results from several single-armed studies, and explores radiation dose escalation in the Virtual HDRB arm. The initial component includes novel technical elements, and will form an important platform set for a definitive phase III study.Trial registration numberANZCTN 12615000223538.https://bmjopen.bmj.com/content/9/8/e030731.full
collection DOAJ
language English
format Article
sources DOAJ
author Jeremy Millar
Jarad Martin
Paul Keall
Shankar Siva
Peter Greer
David Christie
Jason Dowling
David Pryor
Peter Chong
Nicholas McLeod
Avi Raman
James Lynam
Joanne Smart
Declan G Murphy
Keen Hun Tai
Lois Holloway
Amy Hayden
Tee Lim
Tanya Holt
Mark Sidhom
spellingShingle Jeremy Millar
Jarad Martin
Paul Keall
Shankar Siva
Peter Greer
David Christie
Jason Dowling
David Pryor
Peter Chong
Nicholas McLeod
Avi Raman
James Lynam
Joanne Smart
Declan G Murphy
Keen Hun Tai
Lois Holloway
Amy Hayden
Tee Lim
Tanya Holt
Mark Sidhom
TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol
BMJ Open
author_facet Jeremy Millar
Jarad Martin
Paul Keall
Shankar Siva
Peter Greer
David Christie
Jason Dowling
David Pryor
Peter Chong
Nicholas McLeod
Avi Raman
James Lynam
Joanne Smart
Declan G Murphy
Keen Hun Tai
Lois Holloway
Amy Hayden
Tee Lim
Tanya Holt
Mark Sidhom
author_sort Jeremy Millar
title TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol
title_short TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol
title_full TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol
title_fullStr TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol
title_full_unstemmed TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol
title_sort trog 18.01 phase iii randomised clinical trial of the novel integration of new prostate radiation schedules with adjuvant androgen deprivation: ninja study protocol
publisher BMJ Publishing Group
series BMJ Open
issn 2044-6055
publishDate 2019-08-01
description IntroductionStereotactic body radiotherapy (SBRT) is a non-invasive alternative to surgery for the treatment of non-metastatic prostate cancer (PC). The objectives of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation (NINJA) clinical trial are to compare two emerging SBRT regimens for efficacy with technical substudies focussing on MRI only planning and the use of knowledge-based planning (KBP) to assess radiotherapy plan quality.Methods and analysisEligible patients must have biopsy-proven unfavourable intermediate or favourable high-risk PC, have an Eastern Collaborative Oncology Group (ECOG) performance status 0-1 and provide written informed consent. All patients will receive 6 months in total of androgen deprivation therapy. Patients will be randomised to one of two SBRT regimens. The first will be 40 Gy in five fractions given on alternating days (SBRT monotherapy). The second will be 20 Gy in two fractions given 1 week apart followed 2 weeks later by 36 Gy in 12 fractions given five times per week (virtual high-dose rate boost (HDRB)). The primary efficacy outcome will be biochemical clinical control at 5 years. Secondary endpoints for the initial portion of NINJA look at the transition of centres towards MRI only planning and the impact of KBP on real-time (RT) plan assessment. The first 150 men will demonstrate accrual feasibility as well as addressing the KBP and MRI planning aims, prior to proceeding with total accrual to 472 patients as a phase III randomised controlled trial.Ethics and disseminationNINJA is a multicentre cooperative clinical trial comparing two SBRT regimens for men with PC. It builds on promising results from several single-armed studies, and explores radiation dose escalation in the Virtual HDRB arm. The initial component includes novel technical elements, and will form an important platform set for a definitive phase III study.Trial registration numberANZCTN 12615000223538.
url https://bmjopen.bmj.com/content/9/8/e030731.full
work_keys_str_mv AT jeremymillar trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT jaradmartin trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT paulkeall trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT shankarsiva trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT petergreer trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT davidchristie trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT jasondowling trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT davidpryor trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT peterchong trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT nicholasmcleod trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT aviraman trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT jameslynam trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT joannesmart trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT declangmurphy trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT keenhuntai trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT loisholloway trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT amyhayden trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT teelim trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT tanyaholt trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
AT marksidhom trog1801phaseiiirandomisedclinicaltrialofthenovelintegrationofnewprostateradiationscheduleswithadjuvantandrogendeprivationninjastudyprotocol
_version_ 1724209093881626624